Carboplatin Shortage Update: What Patients Need to Know in 2026

The carboplatin shortage, which began in April 2023, has become one of the most consequential and long-lasting drug shortages in modern oncology. For patients undergoing chemotherapy that includes carboplatin — for ovarian cancer, lung cancer, breast cancer, and many other diagnoses — the shortage has created real treatment disruptions, delays, and stress. Here is the most up-to-date picture of where things stand in 2026.

Current Shortage Status (2026)

As of April 2026, carboplatin remains on the FDA's active drug shortage list. According to the ASHP shortage tracker (last updated April 28, 2026):

Fresenius Kabi has its 10 mg/mL 60 mL vials on back order, with an estimated release date of early May 2026.

Pfizer has its 5 mL, 15 mL, and 45 mL vials available in limited supply with weekly releases — meaning allocations are tight and distributed on a first-come basis.

Accord, BPI Labs, and Eugia US are among the other active manufacturers, though availability varies by region and distributor.

How Did We Get Here? A Timeline

Early 2023: Intas Pharmaceuticals (Accord's parent) received an FDA import alert related to quality violations at their Ahmedabad, India plant, removing a major source of US carboplatin supply.

April 2023: FDA officially records carboplatin as entering shortage.

May–June 2023: NCCN survey reveals 93% of cancer centers report carboplatin shortages. ASCO estimates up to 500,000 patients affected.

Mid-2023: FDA works with manufacturers to increase production; GPO networks begin distributing inventory through supply-sharing arrangements.

2024–2025: Supply partially stabilizes but carboplatin remains on allocation. Seven manufacturers have historically discontinued production, thinning the supplier base permanently.

April 2026: Shortage remains active per ASHP and FDA databases, with some vial sizes on back order.

Why Is the Shortage Taking So Long to Resolve?

Carboplatin is a sterile generic injectable drug that sells for roughly $2 per vial at the manufacturer level. That razor-thin profit margin means manufacturers have little economic motivation to build reserve production capacity. When disruptions occur, there is no buffer — and spinning up new manufacturing capacity for a complex sterile injectable can take months or years of regulatory review and facility investment. Research published in 2025 identified manufacturing quality problems and dependency on limited sources as factors affecting all oncology drugs in shortage.

The FDA Drug Shortage Database identified 270 drugs in shortage as of March 2025, with about 8% being chemotherapy agents. Carboplatin is among the highest-priority items on that list.

How Does the Shortage Affect Patient Care?

For patients, the shortage means:

Treatment delays when your infusion center runs out of their weekly allocation

Potential dose reductions to stretch available supply

Triage situations where providers must prioritize patients receiving curative-intent treatment

Anxiety and uncertainty about whether your scheduled treatments will proceed as planned

What Can You Do Right Now?

Ask your oncology team about your clinic's current carboplatin supply status and whether your upcoming cycle is secured.

Start preparing 2–3 weeks ahead of each scheduled infusion date, not the day before.

Ask whether your care team has identified a backup infusion center in case your primary clinic exhausts its supply.

You can also use medfinder to find which pharmacies and infusion centers near you have carboplatin available. medfinder calls on your behalf so you don't have to spend hours on hold. See also our article on alternatives to carboplatin for what your oncologist might consider if supply is unavailable.